First Time Loading...
A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 4.07 USD 3.56% Market Closed
Updated: Apr 29, 2024
Section:
 

Wall Street
Price Targets

AQST Price Targets Summary
Aquestive Therapeutics Inc

Wall Street analysts forecast AQST stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AQST is 9.18 USD with a low forecast of 7.07 USD and a high forecast of 12.6 USD.

AQST Lowest Forecast
Wall Street Target
7.07 USD
74% Upside
AQST Average Forecast
Wall Street Target
9.18 USD
126% Upside
AQST Highest Forecast
Wall Street Target
12.6 USD
210% Upside
Lowest
Price Target
7.07 USD
74% Upside
Average
Price Target
9.18 USD
126% Upside
Highest
Price Target
12.6 USD
210% Upside

AQST Last Price Targets
Aquestive Therapeutics Inc

The latest public price target was made on Apr 11, 2024 by David Amsellem from Piper Sandler , who expects AQST stock to rise by 146% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
David Amsellem
Piper Sandler
10 USD
Upside 146%
2 weeks ago
Apr 11, 2024
Piper Sandler Starts Aquestive Therapeutics (AQST) at Overweight, 'he risk/reward profile associated with AQST shares is attractive'
StreetInsider
Raghuram Selvaraju
H.C. Wainwright
9 USD
Upside 121%
1 month ago
Mar 18, 2024
Aquestive Therapeutics (AQST) PT Raised to $9 at H.C. Wainwright
StreetInsider
Francois Brisebois
Oppenheimer
12 USD
Upside 195%
1 month ago
Mar 15, 2024
Aquestive Therapeutics (AQST) PT Raised to $12 at Oppenheimer
StreetInsider
David Amsellem
Piper Sandler
Price Target 10 USD
Upside/Downside 146%
View Source
Raghuram Selvaraju
H.C. Wainwright
Price Target 9 USD
Upside/Downside 121%
View Source
Francois Brisebois
Oppenheimer
Price Target 12 USD
Upside/Downside 195%
View Source
Aquestive Therapeutics Inc Competitors:
Price Targets
VIRP
Virbac SA
1% Upside
PFE
Pfizer Inc
25% Upside
W
016580
Whanin Pharm Co Ltd
55% Upside
AXSM
Axsome Therapeutics Inc
75% Upside
VIRP
Virbac SA
1% Upside
PFE
Pfizer Inc
25% Upside
W
016580
Whanin Pharm Co Ltd
55% Upside
AXSM
Axsome Therapeutics Inc
75% Upside
B
600085
Beijing Tongrentang Co Ltd
41% Upside
P
603566
Pulike Biological Engineering Inc
51% Upside
600572
Zhejiang CONBA Pharmaceutical Co Ltd
10% Upside
C
CLN
Celon Pharma SA
12% Upside

Revenue
Forecast

Revenue Estimate
Aquestive Therapeutics Inc

For the last 6 years the compound annual growth rate for Aquestive Therapeutics Inc's revenue is -5%. The projected CAGR for the next 3 years is 20%.

-5%
Past Growth
20%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Aquestive Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Aquestive Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-50%
Average Miss
What are analyst estimates?

See Also

Summary
AQST intrinsic value, competitors valuation, and company profile.
DCF Valuation
AQST stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AQST stock valuation using valuation multiples.
Wall Street Estimates
AQST price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AQST stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AQST's stock price target?
Price Target
9.18 USD

According to Wall Street analysts, the average 1-year price target for AQST is 9.18 USD with a low forecast of 7.07 USD and a high forecast of 12.6 USD.

What is Aquestive Therapeutics Inc's Revenue forecast?
Projected CAGR
20%

For the last 6 years the compound annual growth rate for Aquestive Therapeutics Inc's revenue is -5%. The projected CAGR for the next 3 years is 20%.

ALPHA SPREAD
Join more than 132,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.